About
CardioRenal Systems, Inc. has developed the only clinically validated solution to the biggest problem today in cardiac surgery and the ICU – Acute Kidney Injury. The technology was granted Breakthrough Designation by the FDA and is CE approved with growing adoption across Europe and the Middle East. The technology was granted Breakthrough Designation by the FDA and is CE approved with growing adoption across Europe and the Middle East.
Technologies
Outlook
Amazon AWS
Mobile Friendly
Google Font API
WordPress.org
Nginx
YouTube
Google Maps
Google Play
iTunes
Remote
Keywords
medical equipment manufacturing
clinical validation
contrast media
renal protection
real-time hydration control
transcatheter aortic valve replacement
renalpro system
cardiopulmonary bypass
dynamic fluid adjustment
urine output response
renal tissue protection
kidney preservation
renal protection technology
post-pci aki prevention
furosemide controlled diuresis
high volume urine flow
medical equipment and supplies manufacturing
renal tissue injury prevention
aki prevention
clinical studies
fda breakthrough device
high-risk patient care
urine output monitoring
medical device innovation
contrast media protection
automated hydration
tavi aki prevention
real-time urine output monitoring
minimally invasive device
healthcare cost reduction
Company Information
-
Employees 36
-
Founded 2014
-
Annual Revenue $5000000
-
Total Funding $64500000
Location
459 Fortune Blvd, Milford, Massachusetts, United States, 01757
